Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ME Therapeutics Holdings Inc C.METX

Alternate Symbol(s):  METXF

Healthcare Biotechnology
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high... see more

Recent & Breaking News (CSE:METX)

    ME Therapeutics Holdings Inc. Appoints Chief Business Officer

    Newsfile October 25, 2024

    ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update

    Newsfile October 22, 2024

    ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

    Newsfile September 18, 2024

    ME Therapeutics to collaborate with NanoVation Therapeutics

    Jocelyn Aspa July 8, 2024

    ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells

    Newsfile July 8, 2024

    CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

    Newsfile June 13, 2024

    ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial

    Newsfile May 29, 2024

    ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities

    Newsfile May 17, 2024

    ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024

    Newsfile April 15, 2024

    ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

    Newsfile March 26, 2024

    ME Therapeutics Announces Closing of Non-Brokered Private Placement

    Newsfile March 6, 2024

    ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

    Newsfile February 27, 2024

    ME Therapeutics Holdings Inc. Announces Listing on the Frankfurt Stock Exchange (FSE) and the Completion of Its Redesigned Website

    Newsfile December 11, 2023

    ME THERAPEUTICS HOLDINGS INC. PROVIDES AN OVERVIEW AND UPDATE ON CURRENT RESEARCH AND DEVELOPMENT PROGRAMS

    Canada NewsWire December 5, 2023